JENNIFER STROOP: Open Payments
NPI 1619687340 · TULLAHOMA, TN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$264 in 14 payments from 10 companies in 2025. Trend: 2023 $135 · 2024 $265 · 2025 $264
Food & beverage: $264
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 3 | $62 |
| Novo Nordisk Inc | 2 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Axsome Therapeutics, Inc. | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $19 |
| Grifols USA, LLC | 1 | $16 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $16 |
| Sumitomo Pharma America, Inc. | 1 | $14 |
| Exact Sciences Corporation | 1 | $14 |
Products named: VRAYLAR, REXULTI, Auvelity, QULIPTA, GVOKE HYPOPEN, MOUNJARO, Prolastin-C Liquid, Ozempic.
Industry payments across TN — which companies pay providers there.
